Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist, and a selective ER degrader (SERD). OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase4 (CDK4)/6 demonstrated robust tumour shrinkage in several xenograft models, including a breast cancer brain metastasis model.